zanzalintinib — Topline data
H2 2026
In May 2026, Exelixis announced that the company expects topline results from the STELLAR-304 trial in the second half of 2026, depending on event rates.Source filing
EXEL biotech catalysts & pipeline
EXELIXIS INC · Data as of 2026-09-08
Upcoming catalysts
zanzalintinib — PDUFA
Dec 3
The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.Source filing